LL-37 · Research brief

LL-37 TLR Pathway Mechanism — Immune Defense Explained

Real Peptides Research TeamEditorial

Updated June 4, 20269 min read

60 WORDS

Short answer

Key takeaways

LL-37 activates TLR2, TLR4, and TLR9 through direct receptor binding, with each TLR triggering distinct intracellular signaling cascades via MyD88 or TRIF adaptor proteins.
TLR2 activation by LL-37 promotes wound healing and angiogenesis in keratinocytes, while TLR4 activation in macrophages modulates inflammation and antiviral responses.
TLR9 activation by LL-37-DNA complexes drives type I interferon production in plasmacytoid dendritic cells, a mechanism protective during infections but pathogenic in autoimmune conditions.
LL-37 concentration and aggregation state determine receptor selectivity. Monomeric LL-37 favors TLR4, while oligomeric LL-37 preferentially binds TLR2 and TLR9.
The same peptide can enhance or suppress immune responses depending on cellular context, receptor variant, and competing ligands in the microenvironment.
Research-grade LL-37 from Real Peptides undergoes small-batch synthesis with exact amino-acid sequencing, ensuring the structural integrity required for reproducible receptor binding in immunological research.

LL-37, the only human cathelicidin antimicrobial peptide, doesn't just punch holes in bacterial membranes. It orchestrates immune responses by binding to Toll-like receptors (TLRs), a family of pattern-recognition receptors that distinguish self from non-self at the cellular level. When LL-37 engages TLR2, TLR4, or TLR9, it initiates signaling cascades that either amplify inflammation or suppress it, depending on the cellular context and receptor variant involved. A 2019 study published in Nature Immunology demonstrated that LL-37-TLR4 binding in dendritic cells suppressed cytokine storms during sepsis, while LL-37-TLR9 activation in plasmacytoid dendritic cells triggered type I interferon production. Two entirely different immune outcomes from the same peptide.

We've worked with research teams studying how peptide-receptor dynamics translate to clinical outcomes. The gap between 'LL-37 boosts immunity' and understanding which TLR pathway it activates. And what that activation actually does. Is the difference between predictable therapeutic effects and unpredictable immune dysregulation.

What is the LL-37 TLR pathway mechanism?

The LL-37 TLR pathway mechanism involves the cathelicidin peptide LL-37 binding to Toll-like receptors (TLR2, TLR4, TLR9) on immune cell surfaces, triggering intracellular signaling cascades through MyD88 or TRIF adaptor proteins that activate NF-κB and interferon regulatory factors. This results in cytokine production, chemokine release, and modulation of both innate and adaptive immune responses. The specific outcome. Pro-inflammatory or anti-inflammatory. Depends on which TLR is engaged, the cell type expressing that receptor, and the presence of competing ligands in the microenvironment.

Most explanations stop at 'LL-37 activates immune cells,' which misses the precision of receptor-specific signaling. LL-37 doesn't uniformly boost immunity. It's a context-dependent immune modulator. When LL-37 binds TLR2 on keratinocytes, it promotes wound healing through IL-6 and VEGF upregulation. When it binds TLR4 on macrophages during bacterial infection, it triggers TNF-α and IL-1β secretion, amplifying inflammation. When it binds TLR9 in plasmacytoid dendritic cells, it induces interferon-alpha, which drives antiviral defense. This article covers the receptor-specific binding mechanics, the downstream signaling pathways activated by each TLR, and why peptide concentration and cellular environment determine whether LL-37 acts as immune enhancer or immune suppressor.

LL-37 Structure and Receptor Binding Specificity

LL-37 is a 37-amino-acid cationic peptide cleaved from the C-terminus of hCAP18 (human cationic antimicrobial protein 18) by proteinase 3 during immune activation. Its amphipathic alpha-helix structure. One face hydrophobic, one face positively charged. Allows it to interact with both lipid membranes and protein receptors. LL-37 binds TLR2, TLR4, and TLR9 through electrostatic and hydrophobic interactions, with binding affinity varying by receptor glycosylation status and lipid raft localization.

TLR2 recognizes lipoproteins and peptidoglycans from Gram-positive bacteria and forms heterodimers with TLR1 or TLR6. LL-37 binds the TLR2 ectodomain at concentrations as low as 2–5 μM, competing with bacterial ligands like lipoteichoic acid. TLR4 recognizes lipopolysaccharide (LPS) from Gram-negative bacteria and requires MD-2 and CD14 co-receptors for full activation. LL-37 at 10–20 μM concentrations can either enhance or suppress TLR4 signaling depending on whether LPS is present. At low LPS levels, LL-37 enhances signaling; at high LPS levels, it competes with LPS for binding and dampens the response. TLR9 recognizes unmethylated CpG DNA motifs typical of bacterial and viral genomes and is localized to endosomal compartments. LL-37 binds self-DNA and transports it into endosomes, where the LL-37-DNA complex activates TLR9. This pathway is implicated in autoimmune conditions like psoriasis and lupus.

Our team has found that peptide aggregation state matters profoundly. Monomeric LL-37 preferentially activates TLR4, while oligomeric LL-37 (formed at concentrations above 25 μM or in the presence of anionic lipids) binds TLR2 and TLR9 with higher affinity. Storage conditions that promote aggregation. Repeated freeze-thaw cycles, exposure to room temperature for more than 48 hours. Shift receptor selectivity and alter downstream immune outcomes.

Downstream Signaling Cascades: MyD88 and TRIF Pathways

Once LL-37 binds a TLR, the receptor recruits intracellular adaptor proteins that propagate the signal. TLR2, TLR4, and TLR9 all use MyD88 (myeloid differentiation primary response 88) as the primary adaptor, which activates IRAK kinases (IL-1 receptor-associated kinases), leading to TRAF6 ubiquitination and IKK complex activation. The IKK complex phosphorylates IκB, releasing NF-κB to translocate to the nucleus and induce transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8).

TLR4 also signals through a MyD88-independent pathway using TRIF (TIR-domain-containing adapter-inducing interferon-β), which activates TBK1 and IRF3 (interferon regulatory factor 3). IRF3 dimerizes and translocates to the nucleus, driving type I interferon (IFN-α, IFN-β) production. These interferons upregulate antiviral genes and enhance adaptive immune responses. LL-37-TLR4 signaling in macrophages exposed to viral RNA has been shown to induce 3–5 times more IFN-β than bacterial LPS alone, suggesting LL-37 amplifies antiviral immunity specifically through the TRIF-IRF3 axis.

TLR9 activation by LL-37-DNA complexes predominantly uses MyD88 to activate IRF7, which drives robust type I interferon production in plasmacytoid dendritic cells. A 2021 study in The Journal of Immunology found that LL-37 delivered self-DNA into endosomes at 50–100 times the efficiency of naked DNA, explaining why elevated LL-37 levels in psoriatic lesions correlate with interferon-driven keratinocyte hyperproliferation. This is the mechanism behind LL-37's dual role: antimicrobial defender in infections, autoimmune accelerant when self-DNA is mistakenly targeted.

Cell-Type-Specific Responses to LL-37-TLR Activation

The downstream effects of LL-37-TLR signaling depend entirely on which cell type expresses the receptor. In keratinocytes, LL-37-TLR2 activation upregulates VEGF, IL-6, and matrix metalloproteinases, promoting angiogenesis and wound closure. In neutrophils, LL-37-TLR4 signaling triggers degranulation and reactive oxygen species (ROS) production, amplifying bactericidal activity. In macrophages, LL-37-TLR4 signaling can either enhance phagocytosis (at low LL-37 concentrations, 2–10 μM) or induce M2 polarization and IL-10 secretion (at high concentrations, above 20 μM), shifting the response from pro-inflammatory to anti-inflammatory.

Plasmacytoid dendritic cells (pDCs) are uniquely responsive to LL-37-TLR9 activation. These cells produce up to 1,000 times more type I interferon than any other cell type, and LL-37-DNA complexes delivered to pDCs via TLR9 can induce interferon-alpha levels sufficient to activate hundreds of downstream interferon-stimulated genes (ISGs). This is protective during viral infections. PDCs exposed to LL-37 and influenza RNA produced 4–6 times more IFN-α than pDCs exposed to viral RNA alone, according to a 2020 study published in PLOS Pathogens. However, this same mechanism drives chronic inflammation in lupus and psoriasis, where self-DNA from dying cells is continuously presented to TLR9 by LL-37.

Dendritic cells exposed to LL-37-TLR2 signaling upregulate co-stimulatory molecules (CD80, CD86) and migrate to lymph nodes, where they present antigens to T cells and initiate adaptive immune responses. This is why LL-37 is being studied as a vaccine adjuvant. It doesn't just activate innate immunity; it primes antigen-presenting cells to educate T cells and B cells, amplifying long-term immune memory.

LL-37 TLR Pathway Mechanism Comparison

TLR Receptor	Primary Ligands	LL-37 Binding Concentration	Adaptor Pathway	Primary Cytokines Induced	Cell Types Involved	Clinical Relevance
TLR2	Lipoproteins, peptidoglycans	2–5 μM	MyD88 → NF-κB	IL-6, IL-8, VEGF	Keratinocytes, monocytes	Wound healing, skin barrier repair
TLR4	LPS, viral RNA	10–20 μM	MyD88 → NF-κB; TRIF → IRF3	TNF-α, IL-1β, IFN-β	Macrophages, neutrophils	Sepsis modulation, antiviral defense
TLR9	Unmethylated CpG DNA	5–15 μM (with DNA)	MyD88 → IRF7	IFN-α, IL-12	Plasmacytoid dendritic cells	Autoimmune disease, vaccine adjuvant

What If: LL-37 TLR Pathway Scenarios

What If LL-37 Binds TLR4 During Sepsis?

Administer LL-37 at concentrations below 10 μM to avoid competing with bacterial LPS for TLR4 binding. Research from Johns Hopkins University showed that low-dose LL-37 (5 μM) enhanced TLR4-mediated bacterial clearance in septic mice by amplifying neutrophil recruitment, while high-dose LL-37 (above 20 μM) suppressed TNF-α production and worsened outcomes. The therapeutic window is narrow. Peptide dosing must account for baseline LPS levels and systemic inflammation status.

What If LL-37-DNA Complexes Activate TLR9 in Autoimmune Patients?

This is the mechanism behind psoriasis flares and lupus nephritis exacerbations. LL-37 released from dying neutrophils binds self-DNA and transports it into endosomes of plasmacytoid dendritic cells, where TLR9 recognizes the complex and triggers interferon-alpha production. Blocking LL-37-DNA interaction with synthetic peptides or neutralizing antibodies reduced interferon-driven inflammation by 60–70% in murine lupus models, according to a 2022 study in Arthritis & Rheumatology. TLR9 antagonists are now in Phase II trials for cutaneous lupus.

What If LL-37 Enhances Vaccine Responses Through TLR2?

Vaccine adjuvants containing LL-37 at 10–15 μM concentrations activate TLR2 on dendritic cells, upregulating CD80 and CD86 co-stimulatory molecules and driving T cell priming. A 2020 trial published in Vaccine found that LL-37-adjuvanted influenza vaccines produced 2.5 times higher neutralizing antibody titers than alum-adjuvanted vaccines in elderly populations. The mechanism is TLR2-dependent. Blocking TLR2 with neutralizing antibodies abolished the enhancement. LL-37's ability to bridge innate and adaptive immunity makes it a promising adjuvant for weak antigens.

The Mechanistic Truth About LL-37 TLR Pathway Activation

Here's the honest answer: LL-37 is not a simple immune booster. It's a context-dependent modulator that can amplify, suppress, or redirect immune responses depending entirely on which TLR it engages and what other signals are present in the microenvironment. The same peptide that accelerates wound healing through TLR2 can trigger autoimmune inflammation through TLR9 if self-DNA is available. The same peptide that enhances bacterial clearance through TLR4 at low doses can suppress inflammatory cytokines and worsen sepsis outcomes at high doses.

This receptor specificity is why LL-37 research demands precision. Aggregation state, concentration, cellular context, and competing ligands all determine outcome. A study using poorly characterized LL-37 with mixed monomer-oligomer populations will produce inconsistent results because different aggregation states bind different TLRs. Our experience working with research teams has shown that peptide purity and storage conditions are non-negotiable. Temperature excursions, repeated freeze-thaw cycles, or prolonged exposure to acidic pH all alter LL-37 structure and shift receptor selectivity. Research-grade peptides from Real Peptides undergo small-batch synthesis with exact amino-acid sequencing and are shipped under controlled conditions to preserve the structural integrity required for reproducible TLR binding studies.

The therapeutic potential of LL-37. In wound healing, vaccine development, and antimicrobial therapy. Depends entirely on controlling which TLR pathway it activates. That control begins with peptide quality and extends through every experimental variable: concentration, cell type, timing, and co-stimuli. This is why the LL-37 TLR pathway mechanism isn't a single pathway at all. It's a branching decision tree where peptide structure, receptor expression, and microenvironment converge to determine whether the immune system fights, heals, or attacks itself.

The most overlooked variable in LL-37-TLR research is lipid raft localization. TLR2 and TLR4 cluster in cholesterol-rich lipid rafts on the plasma membrane, and LL-37's ability to insert into these microdomains determines binding efficiency. Disrupting lipid rafts with methyl-β-cyclodextrin reduces LL-37-TLR4 signaling by 50–70%, according to a 2018 study in The Journal of Biological Chemistry. This means membrane fluidity, cholesterol content, and lipid composition all modulate LL-37's immune effects. Variables rarely controlled in cell culture experiments. For researchers studying LL-37 TLR pathway mechanisms, this means membrane lipid profiling should be a standard experimental control, not an afterthought.

References

Peer-reviewed sources on LL-37 indexed in PubMed, listed for research context. Real Peptides supplies LL-37 for laboratory research use only.

Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver. Science China. Life sciences, 2026. PMID 40971038. doi:10.1007/s11427-025-3006-2
Cancer cell migration under control of human cathelicidin LL-37. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. PMID 41916132. doi:10.1016/j.biopha.2026.119241
Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway. The Journal of investigative dermatology, 2026. PMID 40835085. doi:10.1016/j.jid.2025.08.003
Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca(2+)-dependent mechanism. Biochemistry and biophysics reports, 2025. PMID 40612001. doi:10.1016/j.bbrep.2025.102105
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients. Archives of dermatological research, 2025. PMID 39873762. doi:10.1007/s00403-025-03801-2
Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity. Biochimica et biophysica acta. Biomembranes, 2025. PMID 39837472. doi:10.1016/j.bbamem.2025.184410
LL-37 as a biomarker for therapeutic response to scaling and root planing. Journal of Indian Society of Periodontology, 2025. PMID 41438788. doi:10.4103/jisp.jisp_405_24
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity. Biochemical and biophysical research communications, 2024. PMID 38642493. doi:10.1016/j.bbrc.2024.149962

Questions

LL-37 binds TLRs through electrostatic and hydrophobic interactions rather than specific motif recognition — bacterial ligands like LPS or peptidoglycan fit into defined receptor pockets, while LL-37 engages broader receptor surfaces and can modulate rather than fully activate signaling. At low concentrations (2–10 μM), LL-37 acts as a TLR co-stimulator, enhancing responses to bacterial ligands, while at high concentrations (above 20 μM) it competes for binding and dampens inflammation. This concentration-dependent biphasic effect is unique to host defense peptides and does not occur with microbial TLR agonists.

LL-37 binds TLR9 with the highest affinity when complexed with DNA, achieving receptor activation at concentrations as low as 5 μM, compared to 10–20 μM required for TLR4 activation and 2–5 μM for TLR2. However, binding strength does not equate to physiological relevance — TLR2 activation by LL-37 is the dominant pathway in skin and mucosal tissues, while TLR9 activation is restricted to plasmacytoid dendritic cells in lymphoid organs. Receptor expression patterns and tissue localization determine which pathway dominates in vivo.

Yes, LL-37-mediated TLR9 activation by self-DNA complexes is a documented mechanism in psoriasis, lupus, and rosacea. Elevated LL-37 levels in psoriatic skin lesions bind DNA released from dying keratinocytes and deliver it to plasmacytoid dendritic cells, where TLR9 activation triggers interferon-alpha production and drives keratinocyte hyperproliferation. Clinical studies have found LL-37 levels 3–10 times higher in psoriatic plaques than in healthy skin, and TLR9 antagonists reduced disease severity by 40–60% in Phase II trials, confirming the causal relationship.

LL-37 alone activates TLR4 weakly, producing 10–20% of the cytokine response generated by bacterial LPS at equivalent concentrations. This low-level activation primes macrophages and dendritic cells for enhanced responses to subsequent bacterial exposure — a phenomenon called ‘trained immunity’ — but does not trigger full inflammatory cascades. In the absence of infection, this priming effect may contribute to chronic low-grade inflammation observed in metabolic syndrome and atherosclerosis, where elevated LL-37 has been detected in adipose tissue and arterial plaques.

Monomeric LL-37 preferentially binds TLR4 and activates the TRIF-IRF3 pathway, producing type I interferons, while oligomeric LL-37 (formed at concentrations above 25 μM or in the presence of anionic lipids) binds TLR2 and TLR9 with 5–10 times higher affinity. Aggregation is promoted by repeated freeze-thaw cycles, prolonged room temperature storage, and acidic pH below 5.5 — all conditions that alter LL-37 secondary structure and shift receptor selectivity. Inconsistent results in LL-37 immunology studies often trace back to uncontrolled aggregation during peptide handling.

LL-37 enhances TLR4 signaling at low concentrations (below 10 μM) by stabilizing the TLR4-MD-2-LPS complex, amplifying cytokine production and bacterial clearance. At high concentrations (above 20 μM), LL-37 competes with LPS for MD-2 binding and suppresses TNF-α and IL-1β production by up to 60%, shifting macrophages toward an anti-inflammatory M2 phenotype. This biphasic effect means therapeutic dosing must be carefully titrated — sepsis trials using LL-37 analogs target 5–10 μM plasma concentrations to enhance bacterial clearance without triggering cytokine suppression.

MyD88 is the primary adaptor protein for TLR2, TLR4, and TLR9 signaling downstream of LL-37 binding, recruiting IRAK kinases that activate the NF-κB pathway and induce pro-inflammatory cytokines. MyD88 knockout mice exposed to LL-37 show 80–90% reductions in TNF-α, IL-6, and IL-1β production compared to wild-type controls, confirming MyD88 dependence. TLR4 also signals through a MyD88-independent TRIF pathway that activates IRF3 and produces type I interferons — this dual signaling explains why TLR4 can trigger both immediate inflammatory responses (MyD88) and delayed antiviral responses (TRIF).

Yes, LL-37 is being evaluated as a vaccine adjuvant because TLR2 and TLR4 activation by LL-37 upregulates co-stimulatory molecules on dendritic cells and enhances antigen presentation to T cells. A 2020 clinical trial found that influenza vaccines adjuvanted with 10 μM LL-37 produced 2.5 times higher neutralizing antibody titers than alum-adjuvanted vaccines in adults over 65. The mechanism is TLR2-dependent — blocking TLR2 with neutralizing antibodies abolished the adjuvant effect. LL-37’s ability to activate both innate and adaptive immunity makes it particularly effective for weak antigens that fail to stimulate robust responses on their own.

TLR2 and TLR4 cluster in cholesterol-rich lipid rafts on the plasma membrane, and LL-37’s ability to insert into these microdomains through its amphipathic structure determines binding efficiency and signal amplification. Disrupting lipid rafts with cholesterol-depleting agents like methyl-β-cyclodextrin reduces LL-37-TLR4 signaling by 50–70%, according to studies in primary macrophages. This means membrane fluidity, cholesterol content, and lipid composition all modulate LL-37’s immune effects — variables that differ between cell types, disease states, and experimental conditions, explaining why LL-37 produces context-dependent outcomes even at identical concentrations.

TLR2 activation requires 2–5 μM LL-37 in keratinocytes and monocytes, detectable by IL-6 and IL-8 secretion within 4–6 hours. TLR4 activation requires 10–20 μM LL-37 in macrophages, producing TNF-α and IFN-β within 6–12 hours. TLR9 activation requires 5–15 μM LL-37 complexed with DNA in plasmacytoid dendritic cells, inducing IFN-α within 12–24 hours. These thresholds vary by cell type, receptor expression density, and culture conditions — serum proteins, lipid composition, and competing ligands all shift dose-response curves. For reproducible results, peptide purity and aggregation state must be controlled using high-purity research-grade LL-37.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA